cH2AX
(S139) foci pATM (S1981) NKX3.1 a b s t r a c t NKX3.1 is an androgen-regulated homeobox gene that encodes a tissue-restricted transcription factor, which plays an important role in the differentiation of the prostate epithelium. Thus, the role of NKX3.1 as a functional topoisomerase I activity enhancer in cell cycle regulation and the DNA damage response (DDR) was explored in prostate cancer cell lines. As an early response to DNA damage following CPT-11 treatment, we found that there was an increase in the cH2AX (S139) foci number and that total phosphorylation levels were reduced in PC-3 cells following ectopic NKX3.1 expression as well as in LNCaP cells following androgen administration. Furthermore, upon drug treatment, the increase in ATM (S1981) phosphorylation was reduced in the presence of NKX3.1 expression, whereas DNA-PKcs expression was increased. Additionally, phosphorylation of CHK2 (T68) and NBS1 (S343) was abrogated by ectopic NKX3.1 expression, compared with the increasing levels in control PC-3 cells in a time-course experiment. Finally, NKX3.1 expression maintained a high cyclin D1 expression level regardless of drug treatment, while total cH2AX
(S139) phosphorylation remained depleted in PC-3, as well as in LNCaP, cells. Thus, we suggest that androgen regulated NKX3.1 maintains an active DDR at the intra S progression and contributes to the chemotherapeutic resistance of prostate cancer cells to DNA damaging compounds. Ó 2011 Elsevier Inc. All rights reserved.
Introduction
Although androgen ablation therapy for prostate cancer leads to decreased tumor cell proliferation and regression of tumor size [1] , the disease recurs within 2-3 years in most organ confined prostate cancer cases [2, 3] . This recurrence may be due to developing tumors retaining functional androgen receptors (AR), which allow the tumors to respond to AR signaling events [4, 5] . In these tumors, ARs can be induced via promiscuous growth factors, which results in transactivation of androgen-regulated genes that might significantly affect tumor progression. The NKX3.1 gene is upregulated by androgens via an AR dependent mechanism in normal prostate epithelium [6, 7] . It encodes a prostate-and testis-specific nucleoprotein with two conserved domains in its wild type isoform (234 aa long). These domains are required for the interaction of NKX3.1 with specific nuclear proteins and DNA [8] . The binding of NKX3.1 negatively modulates AR transcription (putatively via target promoter association) and subsequent signaling events in prostate cells. Its expression also contributes to both cell cycle and cell death machinery by increasing p53 acetylation and through subsequent stabilization of the MDM2-dependent mechanism [9] . However, as part of the Groucho complex, NKX3.1 is required to repress transcription with its loss resulting in prostatic epithelial dysplasia and benign hyperplasia of the rat prostate [10, 11] . Ouyang et al., have shown that NKX3.1 suppresses tumor initiation by protecting the cell against oxidative damage via transcriptional regulation of the pro-oxidant enzyme levels [12, 13] . TOPORS, a strong E3 ubiquitin ligase, promotes proteasomal degradation of NKX3.1 through direct interaction, predisposing cells to oncogenic transformation by providing an irreversible growth advantage as the first steps in prostate carcinogenesis [14] . Recently, it has been reported that NKX3.1 relocates to the nucleus and enhances the cleavage and re-ligation abilities of the topoisomerase I (topo I) enzyme through direct association [15, 16] . ATM and ATR activities are influenced by NKX3.1 expression, which protects cells against IR-and mitomycin C-induced DNA damage [17] . Thus, the DNA damage response is more efficient in cells in the presence of NKX3.1 expression; this report provides useful insights into our understanding of the DDR as well as therapy resistance of LNCaP cells upon DNA damage. We hypothesize that NKX3.1 basal expression protects cells against oxidative damage and/or maintains the constitutive DNA damage response in prostate cells through an unknown mechanism and thus is required to suppress cancer initiation in prostate epithelia [12, 13] .
In our study, CPT-11 (a semi-synthetic form of camptothecin) was used as a damage inducer to generate ''double strand'' DNA breaks (DSBs) during replication. In androgen-responsive (native NKX3.1 expressing) LNCaP and in the hormone-independent prostate cell line PC-3 (forced NKX3.1 expression), drug induced H2AX (S139) and ATM (S1981) phosphorylation, as well as foci formations were investigated after short (0.5 and 4 h) and long (24 h) exposures of CPT-11. Thus, we determined that the phosphorylation status and the foci number are regulated in prostate cells by NKX3.1 expression in a time-dependent manner. Therefore, we propose that as a hormone responsive factor NKX3.1 suppresses the initiation of prostate cancer by deregulating the oxidative stress and cell growth, which, upon DNA damage, contributes to therapy resistance by promoting repair response and cyclin D1 expression in castration resistant prostate tumors. Considering this evidence, NKX3.1 might be an important regulator of the DDR in the prostate epithelium for maintaining genome fidelity against cancer progression.
Materials and methods

Constructs and antibodies
NKX3.1 cDNA (accession number AF249669) was used for the construction of pcDNA4-NKX3.1 wild type (234 aa) (Invitrogen, US) [7] . ATM, pATM (S1981) , RAD50, and Cyclin D1 mouse monoclonal, and DNA-PK rabbit polyclonal antibodies were purchased from Santa Cruz Biotechnology Inc. (Bergheim, Germany). cH2AX (S139) mouse monoclonal antibody was purchased from Millipore (US). The NKX3.1 rabbit polyclonal antibody was a kind gift from Dr. Fahri Saatcioglu, from University of Oslo, Norway, and the b-actin antibody (Sigma) was a kind gift from Dr. Buket Kosova of Ege University, Izmir, Turkey. Alexa-fluor488-and 594-conjugated secondary antibodies were also purchased from Invitrogen (Carlsbad, US). Primary and secondary antibodies were used at a concentration range of 0.2 to 2 lg/ml.
Propagation and androgen induction
Androgen-responsive LNCaP cells (passage number [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] were propagated in RPMI1640 (Invitrogen, UK) medium supplemented with 10% heat-inactivated FBS (Invitrogen, UK). Cells were serum starved in the presence of 2% for 48 h and 0.5% for an additional 24 h in CT-FBS containing RPMI1640. R1881 (10 À8 M) inductions were performed for 24 h, while the cells were maintained in serum-starved conditions [7, 18, 19] . Irinotecan (hereafter termed CPT-11; Campto Ò ) (10 lg/ml) was used in all treatments for an additional 0.5, 4 or 24 h after androgen treatment.
NKX3.1 transfection
PC-3 cells were propagated in DMEM/Ham's F12 medium (Invitrogen, UK), supplemented with 5% FBS, and transfection was performed using Fugene HD (Roche, Germany) according to manufacturer's recommendations. Briefly, 3 ll of Fugene HD was dissolved in 100 ll of media and incubated for 5 min. Next, 1 lg of pcDNA4-NKX3.1 DNA was diluted into the mixture, incubated for 15 min, and then applied to cells grown in 55 mm tissue culture flasks drop-wise. Cells were treated for the appropriate time and harvested for further studies.
Immunoblot
Cells were lysed with ice-cold modified RIPA buffer (1% Nonidet P-40, 50 mM Tris HCl pH 7.4, 0.25% Na-deoxycholate, 150 mM NaCl), including 1 mM NaF, 1 mM EDTA, 1 mM Na3VO4, and complete protease and phosphatase inhibitor cocktails (Roche, Germany) unless otherwise indicated. Protein separation was performed using 6-15% SDS-PAGE gels and immobilized onto PVDF membranes (Amersham, UK and/or SantaCruz, Germany) using a wet transfer blotter. Briefly, membranes were blocked using TBS-T (Tris-Base-Saline containing 0.1% Tween 20) containing either 5% skim milk (w/v) or 1% BSA for anti-phospho-antibodies. Antibody incubations were performed using TBS-T containing 0.5% dry milk for 1 h at RT or overnight at 4°C. Membranes were developed using 2 ml ECL plus reagent (Amersham, UK) for 5 min and were photographed using Kodak X-ray films in a dark room.
Immunofluorescence (IF) labeling and microscopy
For the detection of cH2AX (S139) foci and NKX3.1 expression, cells were grown on cover slips, on which transfection and treatment were performed. Cells were rinsed in PBS and fixed with 4% paraformaldehyde for 1 h at RT. Cells were then permeabilized with 0.2% triton X-100-containing PBS and blocked for 5 min using 1% BSA in PBS buffer before incubation with primary antibodies. Antibodies were added for 1 h, and samples were washed with PBS twice. Secondary antibody incubations were performed at RT for 20 min using Alexa-Fluor488/594 (anti-mouse) or AlexaFluor594/488 (anti-rabbit) antibody (Invitrogen, USA). Finally, cells were washed four times with PBS, mounted in 30% glycerol-PBS containing DAPI (0.5 lg/ml), and analyzed immediately using a Leica DMIL fluorescent microscope (Leica, Germany). Images were captured using the Leica image software (LAS).
Cell growth assay
The xCELLigence System (Roche) for real-time cell analysis of impedance-based signals was used for the quantitative determination of cell proliferation. PC-3 cells were transfected with vector or the full length NKX3.1 expression plasmid, trypsinized 24 h after transfection and plated into 96-well plates at three different densities (2, 4, 8 Â 10 3 cells/well). LNCaP cells were induced with R1881, and cells were grown for 24 h post transfection/induction and treated with CPT-11. The decreasing impedance was measured in real time every 30 min according to the manufacturer's instructions (xCELLigence, Roche, Germany) and plotted as growth rate.
Flow cytometry and analysis
Cell cycle distribution of cH2AX (S139) and pATM (S1981) was studied using flow cytometry following CPT-11 treatment in androgentreated LNCaP or NKX3.1 transfected PC-3 cells using a FACSCanto (BD Biosciences, USA). Briefly, after transfection and/or treatment, cells were collected into PBS and were fixed with 100% cold (À20°C) ethanol in a drop-wise manner. Next, cells were labeled with specific (cH2AX (S139) and/or NKX3.1 antibody at a 1:250 or 1:500 dilution, respectively) and secondary antibody conjugated with Alexa-flour 488 (1:1000) as described above. Bivariate readings were performed subsequent to PI staining, and cH2AX
(S139) levels were plotted versus DNA content using the FacsDiva 5.0.3 software.
Image analysis and statistical calculations
Image J software was used to perform IF counts and measurements [20] . Expression densities were measured for each nucleus, and the number of foci was counted. (1) The expression level and/ or average foci counts were classified into expression groups depending on density, which were given in Table 1 
Results and discussion
Hormone-responsive tumors, including those of the breast, uterus and prostate were recently reported to have alterations in the expression of hormone responsive factors. These factors might have roles in maintaining genome stability [21] [22] [23] [24] . We report that functional NKX3.1, the prostate-and testis-restricted homeoboxcontaining factor, activates DNA damage response upon topoisomerase I inhibition in prostate cells. (Fig. 1A) . As the number of foci per nucleus was variable, cells were grouped by means of cH2AX (S139) foci number, as shown in Table 1 (<1, 1-20, 20-50 and >50 foci/nucleus). In the absence of NKX3.1 expression, the baseline number of foci was <1 and increased by 38 and 54% at 0.5 and 4 h of CPT-11 treatment, respectively. The ectopic expression of NKX3.1 significantly reduced cells with foci by 34 and 31% after 0.5 and 4 h of CPT-11 treatment, respectively (Fig. 1B) . The average number of foci for control, vector and NKX3.1-expressing cells were 100 ± 17, 86 ± 26 and 15 ± 14, respectively (Fig. 1C) . Control and vector-transfected cells (number of cells; n = 8 and 66, respectively) had no significant difference in foci number regardless of CPT-11 treatment ( ⁄ p = 0.058). NKX3.1-expressing cells had decreased (average) foci numbers compared with the vector ( ⁄⁄ p < 0.01). NKX3.1-expressing cells have a lower proliferation rate, and CPT-11 treatment further decreased the growth rate of both control and NKX3.1-expressing cells. These data suggest that NKX3.1-positive cells are prone to develop chemo-resistance to therapy depending on exposure time and dose. Moreover, using flow cytometry, S phase cells had higher cH2AX (S139) and pATM (S1981) phosphorylations (highest at 24 h) compared with S phase cells in the presence of NKX3.1 following CPT-11 treatments (Suppl. Fig. 1 ). Because PC-3 cells accumulated more in the intra S phase upon treatment (30% at 24 h), the arrest observed at NKX3.1 expression was significantly suppressed (reduced to 14%) (Fig. 2A) ; furthermore, cH2AX
(S139) and pATM (S1981) were decreased (Suppl. Fig. 1 and Fig. 2B ). Overall, the data suggest that NKX3.1 has a regulatory role for genome maintenance in prostate cells through activation of the DNA damage response. . In comparison, NKX3.1 cells had higher constitutive baseline levels of phosphorylation, which were reduced in a time-dependent manner upon CPT-11 treatment (Fig. 3A and B) , suggesting that the DDR was constitutively activated upon NKX3.1 expression in the PC-3 prostate cells. Phosphorylations of CHK2 (T68) and NBS1 (S343) consistently followed changes of pATM (S1981) , while the expression of the CHK2 was not induced until 4 h and DNA-PKcs remained constant in the absence of NKX3.1, whereas they were profoundly increased in the presence of NKX3.1 upon CPT-11 ( Fig. 3) . Additionally, cyclin D1 expression was found decreased, leading to arrest of cell growth in the absence of NKX3.1 ( Fig. 2A) , which was restored with transient expression of NKX3.1 ( Fig. 3 and Suppl. Fig. 2A ). The nuclear localized cyclin D1 expression was measured (intensity) using image J software from microscopic images. The percentage of cells expressing cyclin D1 (with a mean intensity >40) increased from 26 to 34% upon NKX3.1 expression. Upon treatment with CPT-11, however, the proportion of cyclin D1 expressing cells increased from 17 to 42% and 20 to 44%, respectively, at both the 4 and 24 h time points compared to controls (Suppl. Fig. 2B ). Therefore, we hypothesize that DDR in native PC-3 cells correlates with the DNA damage status, depending on exposure time, where the cH2AX (S139) level is kept low and nuclear localized cyclin D1 expression is maintained at a high level by NKX3.1 expression (Suppl. Fig. 2C ). This result may be the consequence of the NKX3.1-mediated enhancement of topoisomerase I re-ligation ability and/or the interaction of HDAC1, which have been previously reported [10] . These results demonstrate that, upon CPT-11 mediated damage, the repair cascade works more efficiently in cells expressing NKX3.1, whose expression is tightly regulated via androgens in normal prostate, prostate cancer and hormone refractory prostate tumors.
Androgen induction leads to loss of cH2AX
(S139) foci formation
The occurrence of cH2AX (S139) foci was repeatedly observed as non-uniformly distributed in LNCaP cells in the absence of androgen. Following drug treatment, these cells exhibited intense cH2AX (S139) foci, with a significant increase in the number of foci per nucleus and a uniform distribution (Fig. 4A) . When cells were treated with the synthetic androgen R1881, the foci formations disappeared. Moreover, when cells were treated with CPT-11 (for 4 or 24 h) in addition to androgen, the foci formations decreased in cells in the presence of NKX3.1 (dashed circles in Fig. 4 ). These data suggest that the loss of foci formation is related to androgens, and perhaps to NKX3.1, in LNCaP cells.
Although androgen-responsive gene expression is thought to be influenced by androgens in all cells evenly [7] [8] [9] , the cells (<1%) that have a low expression level of NKX3.1 exhibited intense foci following drug treatment (9 and 12% for 4 and 24 h, respectively; marked with continuous circles in Fig. 4A ). Hence, this is a moderate event in LNCaP cells as they are grown in culture without Table 1 When the counts were performed using image J software from captured images using immunofluorescence microscopy, cells were grouped into four different categories according to intensity observed (mean expression per cell). The cH2AX androgens, and subsequent androgen treatment results in a substantial decrease in foci formation, leading to an increase in the growth rate. We consistently observed that the LNCaP growth rate slows for 18 h after androgen administration, which may be related to either morphological alterations or repair activation, resulting in an increased growth rate (as measured using impedance values). Although no difference was observed after 4 h of treatment using flow cytometry (Suppl. Fig. 4A ), the real-time growth assay demonstrated that there was a significant (p < 0.01) arrest with CPT-11 treatment in LNCaP cells, regardless of androgen treatment (Fig. 4B ). In the presence of androgens, cH2AX
phosphorylation decreased in the G1 phase, suggesting that cells can tolerate the DNA damage in G1/S transition, and progress through the cell cycle (Fig. 4B ).
To determine if the cH2AX (S139) phosphorylation status is related specifically to androgens, we included estrogen treatment in our study. While androgen administration decreased the number of cH2AX
(S139) foci and the phosphorylation status, estrogen (S139) is significant, which was demonstrated using western blot analysis.
resulted in a slight change (Fig. 4C ). This effect following estrogen treatment may be due to the mutant (T877A) androgen receptor LBD (ligand-binding domain), which accommodates different hormones in LNCaP cells [25, 26] . Therefore, we concluded that treatment with androgen or estrogen either abrogates the phosphorylation via direct interaction or activates the DDR upon DNA damage putatively via a hormone-responsive factor. Thus, NKX3.1 overexpression in PC-3 cells results in a distinct response to topo I inhibition, which was similar in LNCaP cells that can be induced with androgens. As it was previously reported that NKX3.1 repressed transcription together with the Groucho complex [11] and regulated the pro-oxidant enzyme expressions by HDAC1 recruitment [13] , NKX3.1 may be the major regulator of transcription, cell cycle and repair in prostate cells [16, 17, 21, 22] .
In conclusion, NKX3.1-mediated activation of DDR restores the intra S phase arrest upon DNA damage and, consequently, leads to reprogramming of the cells at the G1/S phase transition. This process is controlled via an androgen action when the damage response is constitutive. Upon exposure to DNA damage, the role of NKX3.1 in DDR with direct interactions as well as its putative role in histone re-organization needs to be assessed in further studies.
